Issue 1, 2013

From natural product to marketed drug: the tiacumicin odyssey

Abstract

Covering: 1975 to 2012

The first members of the tiacumicin family of antibiotics, encompassing more than 40 compounds, were isolated in 1975. Structurally, the core aglycon is an 18-membered macrolactone having two conjugated diene units, one isolated double bond, 5 stereogenic centers and most often, at least one glycosidic linkage. Tiacumicin B, a RNA synthesis inhibitor, is a narrow-spectrum antibiotic against clostridia. For the treatment of Clostridium difficile infection (CDI), it has the same cure rate as vancomycin but with lower relapse rate and was approved by the FDA in May 2011. The aim of this review is to present an overview of the chemistry and biology of tiacumicins since their discovery.

Graphical abstract: From natural product to marketed drug: the tiacumicin odyssey

Article information

Article type
Review Article
Submitted
24 Jul 2012
First published
30 Oct 2012

Nat. Prod. Rep., 2013,30, 161-174

From natural product to marketed drug: the tiacumicin odyssey

W. Erb and J. Zhu, Nat. Prod. Rep., 2013, 30, 161 DOI: 10.1039/C2NP20080E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements